Supernus Pharmaceuticals: Funding, Investors & Team (Oct 2026)
We are a pharmaceutical firm dedicated to creating and marketing medications to treat disorders of the central nervous system (CNS). During the past 30 years, we have developed our substantial product development expertise as a separate development organisation, a US subsidiary of Shire plc, and, most recently, as Supernus Pharmaceuticals Inc. We use our own specialty sales team to promote our drugs in the United States, and we look for strategic partnerships with other pharmaceutical firms to licence our treatments abroad. For the treatment of attention deficit/hyperactivity disorder (ADHD) in children aged 6 to 17, we provide Qelbree® (viloxazine extended-release).
Supernus Pharmaceuticals has raised $150M across 1 funding round on record, the most recent an undisclosed round of $150M announced in Feb 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Supernus Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Feb 2023.
Supernus Pharmaceuticals Funding Rounds
Supernus Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Supernus Pharmaceuticals Funding Compared to Other Biotechnology Startups
Supernus Pharmaceuticals' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Supernus Pharmaceuticals in Biotechnology and Rockville
Companies Similar to Supernus Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Supernus Pharmaceuticals Funding FAQs
What does Supernus Pharmaceuticals do?
We are a pharmaceutical firm dedicated to creating and marketing medications to treat disorders of the central nervous system (CNS). During the past 30 years, we have developed our substantial product development expertise as a separate development organisation, a US subsidiary of Shire plc, and, most recently, as Supernus Pharmaceuticals Inc. We use our own specialty sales team to promote our drugs in the United States, and we look for strategic partnerships with other pharmaceutical firms to licence our treatments abroad. For the treatment of attention deficit/hyperactivity disorder (ADHD) in children aged 6 to 17, we provide Qelbree® (viloxazine extended-release).
How much funding has Supernus Pharmaceuticals raised?
Supernus Pharmaceuticals has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Feb 2023.
When did Supernus Pharmaceuticals last raise funding?
Supernus Pharmaceuticals' most recent funding round on record is an undisclosed round of $150M, announced in Feb 2023.
Who is the CEO of Supernus Pharmaceuticals?
Jack A Khattar is listed as CEO at Supernus Pharmaceuticals.
Where is Supernus Pharmaceuticals headquartered?
Supernus Pharmaceuticals is based in Rockville, Maryland, United States.
How many employees does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals is in the 501-1000 employee band.
How does Supernus Pharmaceuticals' funding compare to other Biotechnology startups?
Supernus Pharmaceuticals' latest round of $150M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Supernus Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Supernus Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.